Does patency matter in patients with critical limb ischemia undergoing endovascular revascularization?
Restenosis is the major drawback in patients undergoing tibial angioplasty. In contrast to earlier observations, tibial patency was shown to impact on clinical outcomes in current randomized trials and is thus attributed more importance. Accordingly, intentions to reduce tibial restenosis have been intensified. Both drug-eluting balloons (DEB) and drug-eluting stents (DES) were shown to reduce tibial restenosis when compared with its plain counterparts. However, both endovascular technologies have its limitations for tibial arterial application. While DEB technology may not address elastic recoil, a pathophysiological mechanism frequently observed in tibial arteries and a significant contributor to restenosis, currently available DES do not fully address tibial arterial lesion morphology. Purpose of the present manuscript is to outline the problem and the incidence of tibial arterial restenosis, its importance on clinical outcomes and to provide an overview on technical developments aimed at its prevention.
Clinical and Interventional Angiology, Inselspital, University Hospital Bern, Switzerland.
Frederic
F
Baumann
Clinical and Interventional Angiology, Kantonsspital Aarau, Switzerland.
Ernst
E
Groechenig
Clinical and Interventional Angiology, Kantonsspital Aarau, Switzerland ; University of Applied Sciences Furtwangen, Villingen-Schwenningen, Germany.
Nicolas
N
Diehm
critical limb ischemia; drug-eluting balloon; drug-eluting stent; infrapopliteal angioplasty; restenosis